Download PDF
Thromb Haemost 2002; 87(01): 58-67
DOI: 10.1055/s-0037-1612944
Review Article
Schattauer GmbH

Plasma Protein Oxidation Is Associated with an Increase of Procoagulant Markers Causing an Imbalance between Pro- and Anticoagulant Pathways in Healthy Subjects

Raimondo De Cristofaro
1   Hemostasis Research Center, Department of Internal Medicine, Catholic University School of Medicine, Rome, Italy
,
Bianca Rocca
1   Hemostasis Research Center, Department of Internal Medicine, Catholic University School of Medicine, Rome, Italy
,
Roberto Marchioli
2   Department of Clinical Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri, Consorzio Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy
,
Raffaele Landolfi
1   Hemostasis Research Center, Department of Internal Medicine, Catholic University School of Medicine, Rome, Italy
› Author Affiliations
Further Information

Publication History

Received 12 June 2001

Accepted after resubmission 25 October 2001

Publication Date:
13 December 2017 (online)

Also available at
    Permissions and Reprints

Summary

The aim of the present study was to investigate whether the overall oxidation state of plasma proteins is associated with changes of circulating pro- and anticoagulant markers in healthy subjects (n = 99, 49 males, 50 females, aged from 6 to 91 yrs.). The carbonyl content of plasma proteins was measured and validated as an ex vivo index of the overall protein oxidation state due to its correlation with the plasma level of o-tyrosine (r = 0.87, P <0.0001), which is a well known oxidized product of L-phenylalanine. Using a multivariate analysis the carbonyl content of plasma protein was positively associated with procoagulant markers such as prothrombin F1 + 2 (r = 0.28, P = 0.0019) and fibrinopeptide A, (FpA) (r = 0.278, P = 0.003), as well as with the soluble derivative of the endothelial protein thrombomodulin (TM) (r = 0.469, P <0.0001). The procoagulant marker of thrombin activity, FpA, was significantly and positively correlated with the anticoagulant product of thrombin, namely the Protein C activation peptide (PCP), only in the tertile with low protein carbonyl content. At higher tertiles this correlation was no longer observed, thus suggesting a detrimental effect of oxidative stress on the TM/Protein C anticoagulant pathway. In 15 subjects with high carbonyl content of plasma protein, treatment for 18 days with 600 mg/d of vitamin E did not substantially modify the protein carbonyl content, the anticoagulant markers APC/PCP, and all procoagulant markers except F1+2, whose value significantly decreased by 25%.

In conclusion, the present study shows that a high plasma protein oxidation ex vivo is associated with an overall hemostatic imbalance, which favors procoagulant markers. Vitamin E treatment in vivo restores only in part the equilibrium between pro- and anticoagulant pathways. This may open the way to further studies aimed at elucidating the mechanisms by which the oxidative stress is linked to activation of the coagulation system in atherothrombotic disorders.

Abbreviations: APC: activated Protein C; F1+2: prothrombin fragment 1+2; FpA: fibrinopeptide A; PCP: Protein C activation peptide; TM: thrombomodulin

Keywords

Protein oxidation - coagulation pathways - antioxidant agents
 

  • References

  • 1 Hazell LJ, Stocker R. Oxidation of low-density lipoprotein with hypochlorite causes transformation of the lipoprotein into a high uptake form for macrophages. Biochem J 1993; 290: 165-72.
    CrossrefPubMedGoogle Scholar
  • 2 Daugherty A, Dunn JL, Rateri DL, Heinecke JW. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 1994; 94: 437-44.
    CrossrefPubMedGoogle Scholar
  • 3 Lusis AJ. Atherosclerosis. Nature 2000; 407: 233-40.
    CrossrefPubMedGoogle Scholar
  • 4 Davies KGA. Oxidation Damage and Repair: Chemical, Biological and Medical Aspects. New York: Pergamon, Elmsford; 1991
    Google Scholar
  • 5 Heinecke JW, Li W, Daehnke HL, Goldstein JA. Dityrosine, a specific marker of oxidation, is synthesized by the myeloperoxidase-hydrogen peroxide system of human neutrophils and macrophages. J Biol Chem 1993; 268: 4069-77.
    PubMedGoogle Scholar
  • 6 Savenkova MI, Mueller DM, Heinecke JW. Tyrosyl radical generated by myeloperoxidase is a physiological catalyst for initiation of lipid peroxidation in low density lipoprotein. J Biol Chem 1994; 269: 20394-400.
    PubMedGoogle Scholar
  • 7 Anderson MM, Hazen SL, Hsu FF, Heinecke JW. Human neutrophils employ the myeloperoxidase-hydrogen peroxide-chloride system to convert hydroxy-amino acids into glycolaldehyde, 2-hydroxypropanal, and acrolein. J Clin Invest 1997; 99: 424-32.
    CrossrefPubMedGoogle Scholar
  • 8 Smith C, Mithcinson MJ, Aruoma OI, Halliwell B. Stimulation of lipid peroxidation and hydroxyl radical generation by contents of human atherosclerotic lesions. Biochem J 1992; 286: 901-5.
    CrossrefPubMedGoogle Scholar
  • 9 Swain J, Guteridge JMC. Prooxidant iron and copper, with ferroxidase and xanthine oxidase activities in human atherosclerotic material. FEBS Lett 1995; 368: 513-5.
    CrossrefPubMedGoogle Scholar
  • 10 Lamb DJ, Mitchinson MJ, Leake DS. Transition metal ions within human atherosclerotic lesions can catalyse the oxidation of low density lipoprotein by macrophages. FEBS Lett 1995; 374: 12-6.
    CrossrefPubMedGoogle Scholar
  • 11 Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study. Lancet 1996; 347: 781-6.
    CrossrefPubMedGoogle Scholar
  • 12 Tribble DL. Antioxidant consumption and risk of coronary heart disease: emphasis on vitamin C, vitamin E, and b-carotene. Circulation 1999; 99: 591-5.
    CrossrefPubMedGoogle Scholar
  • 13 Collaborative Group of the primary prevention project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 2001; 357: 189-95.
    CrossrefPubMedGoogle Scholar
  • 14 Refsgaard HHF, Tsai L, Stadtman ER. Modifications of proteins by polyunsaturated fatty acid peroxidation products. Proc Natl Acad Sci USA 2000; 97: 611-6.
    CrossrefPubMedGoogle Scholar
  • 15 Stadtman ER. Protein oxidation and aging. Science 1992; 257: 1220-4.
    CrossrefPubMedGoogle Scholar
  • 16 Rota S, McWilliam NA, Baglin TP, Byrne CD. Atherogenic lipoproteins support assembly of the prothrombinase complex and thrombin generation: modulation by oxidation and vitamin E. Blood 1998; 91: 508-15.
    PubMedGoogle Scholar
  • 17 Weinstein EA, Li H, Lawson JA, Rokach J, FitzGerald GA, Axelsen PH. Prothrombinase acceleration by oxidationly damaged phospholipids. J Biol Chem 2000; 275: 22925-30.
    CrossrefPubMedGoogle Scholar
  • 18 Shacter E, Williams JA, Levine RL. Oxidation modification of fibrinogen inhibits thrombin catalyzed clot formation. Free Radic Biol Med 1995; 18: 815-21.
    CrossrefPubMedGoogle Scholar
  • 19 De Cristofaro R, Landolfi R. Oxidation of human α-thrombin by the myeloperoxidase-H2O2-chloride system: structural and functional effects. Thromb Haemost 2000; 83: 253-61.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Oates AM, Salem HH. The binding and regulation of Protein S by neutrophils. Blood Coagul Fibrinol 1991; 02: 601-7.
    CrossrefPubMedGoogle Scholar
  • 21 Stief TW, Aab A, Heimburger N. Oxidation inactivation of purified human alpha-2-antiplasmin, antithrombin III, and C1-inhibitor. Thromb Res 1988; 49: 581-9.
    CrossrefPubMedGoogle Scholar
  • 22 Esmon CT. Regulation of blood coagulation. Biochim Biophys Acta 2000; 1477: 349-60.
    CrossrefPubMedGoogle Scholar
  • 23 Ishii H, Uchiyama H, Kazama M. Soluble thrombomodulin antigen in conditioned medium is increased by damage of endothelial cells. Thromb Haemost 1991; 65: 618-23.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Lentz SR, Sadler JE. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 1991; 88: 1906-14.
    CrossrefPubMedGoogle Scholar
  • 25 Glaser BB, Morser J, Clarke JH, Blasko E, McLean K, Kuhn I, Chang RJ, Lin JH, Vilander L, Andrews WH, Light DR. Oxidation of a specific methionine in thrombomodulin by activated neutrophil products blocks cofactor activity. J Clin Invest 1992; 90: 2565-73.
    CrossrefPubMedGoogle Scholar
  • 26 Lee BL, Chua SC, Ong HY, Ong CN. High-performance liquid chromatographic method for routine determination of vitamin A and E and β-carotene in plasma. J Chromatogr 1992; 581: 41-7.
    CrossrefPubMedGoogle Scholar
  • 27 Bauer KA, Kass BL, Beeler DL, Rosenberg RD. Detection of Protein C activation in humans. J Clin Invest 1984; 74: 2033-41.
    CrossrefPubMedGoogle Scholar
  • 28 Bauer KA, Weiss LM, Sparrow D, Vokonas PS, Rosenberg RD. Agingassociated changes in indices of thrombin generation and Protein C activation in humans. J Clin Invest 1987; 80: 1527-34.
    CrossrefPubMedGoogle Scholar
  • 29 Fraker PJ, Speck JC. Protein and cell iodination with a sparingly soluble chloroamide, 1,3,4,6,-tetrachloro-3a,6a-diphenyl-glycoluril. Biochem Biophys Res Commun 1978; 161: 849-53.
    PubMedGoogle Scholar
  • 30 Espana F, Zuazu I, Vicente V, Estelles A, Marco P, Aznar J. Quantification of circulating activated protein C in human plasma by immunoassays – enzyme levels are proportional to total protein C levels. Thromb Haemost 1996; 75: 56-61.
    PubMedGoogle Scholar
  • 31 Oliver CN, Bong-whan A, Moerman EJ, Goldstein S, Stadtman ER. Age-related changes in oxidized proteins. J Biol Chem 1987; 262: 5488-91.
    PubMedGoogle Scholar
  • 32 Ishimutsu S, Fujimoto S, Ohara A. Determination of m-tyrosine and o-tyrosine in human serum by high-performance liquid chromatography with fluorimetric detection. J Chromatogr Biomed Applic 1986; 378: 222-5.
    CrossrefPubMedGoogle Scholar
  • 33 Faust SN, Levin M, Harrison OB, Goldin RD, Lockhart MS, Kondaveeti S, Laszik Z, Esmon CT, Heyderman RS. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 2001; 345: 408-16.
    CrossrefPubMedGoogle Scholar
  • 34 Nossel HL, Ti M, Kaplan KL, Spanondis K, Soland T, Butler Jr VP. The generation of fibrinopeptide A in clinical blood samples. Evidence for thrombin activity. J Clin Invest 1976; 58: 1136-44.
    CrossrefPubMedGoogle Scholar
  • 35 Gruber A, Griffin J. Direct detection of activated Protein C in blood from normal subjects. Blood 1992; 79: 2340-8.
    PubMedGoogle Scholar
  • 36 Mari D, Mannucci PM, Coppola R, Botasso B, Bauer KA, Rosenberg RD. Hypercoagulability in Centenarians: the paradox of successful aging. Blood 1995; 85: 3144-9.
    PubMedGoogle Scholar
  • 37 Picozzi M, Landolfi R, De Cristofaro R. Effects of protons on the thrombinfibrinogen interaction. Eur J Biochem 1994; 219: 1013-21.
    CrossrefPubMedGoogle Scholar
  • 38 Patrignani P, Tacconelli S, Seta F, Bucciarelli T, Ciabattoni G, Alessandrini P, Mezzetti A, Santini G, Sciulli MG, Cipollone F, Davi G, Gallina P, Bon GB, Patrono C. Effects of vitamin E supplementation on F2-isoprostane and thromboxane biosynthesis in healthy cigarette smokers. Circulation 2000; 102: 539-45.
    CrossrefPubMedGoogle Scholar
  • 39 Hawkins CL, Davies M. Hypochlorite-induced oxidation of proteins in plasma: formation of chloramines and nitrogen-centred radicals and their role in protein fragmentation. Biochem J 1999; 340: 539-48.
    CrossrefPubMedGoogle Scholar
  • 40 Leeuwenburgh C, Rasmussen JE, Hsu FF, Mueller DM, Pennathur S, Heinecke JW. Mass spectrometric quantification of markers for protein oxidation by tyrosyl radical, copper, and hydroxyl radical in low density lipoprotein isolated from human atherosclerotic plaques. J Biol Chem 1997; 272: 3520-6.
    CrossrefPubMedGoogle Scholar
  • 41 Stadtman ER. Oxidation of free amino acids and amino acid residues in proteins by radiolysis and by metal-catalyzed reactions. Annu Rev Biochem 1993; 62: 797-821.
    CrossrefPubMedGoogle Scholar
  • 42 Wang Z, Ciabattoni G, Creminon C, Lawson J, Fitzgerald GA, Patrono C, Maclouf J. Immunological characterization of urinary 8-epi-prostaglandin F2α excretion in man. J Pharmacol Exp Ther 1995; 275: 94-100.
    PubMedGoogle Scholar
  • 43 Takano S, Kimura S, Ohdama S, Aokin N. Plasma thrombomodulin in health and diseases. Blood 1990; 76: 2024-9.
    PubMedGoogle Scholar
  • 44 Sakamaki F, Kyotani S, Nagaya N, Sato N, Oya H, Satoh T, Nakanishi N. Increased plasma P-selectin and decreased thrombomodulin in pulmonary arterial hypertension were improved by continuous prostacyclin therapy. Circulation 2000; 102: 2720-5.
    CrossrefPubMedGoogle Scholar
  • 45 Fuentes-Prior P, Iwanaga Y, Huber R, Paglia R, Rumennik G, Morser J, Light DR, Bode W. Structural basis for the anticoagulant activity of the thrombinthrombomodulin complex. Nature 2000; 404: 518-25.
    CrossrefPubMedGoogle Scholar
  • 46 Halliwell B. Oxidants and human disease: some new concepts. FASEB J 1987; 01: 358-64.
    CrossrefPubMedGoogle Scholar
  • 47 Pratico D, Ferro D, Iuliano L, Rokach J, Conti F, Valesini G, FitzGerald GA, Violi F. Ongoing prothrombotic state in patients with antiphospholipid antibodies: a role for increased lipid peroxidation. Blood 1999; 93: 3401-7.
    PubMedGoogle Scholar
  • 48 Baynes JW, Thorpe SR. Role of oxidation stress in diabetic complications. A new perspective on an old paradigm. Diabetes 1999; 48: 1-9.
    CrossrefPubMedGoogle Scholar
  • 49 Davi G, Di Minno G, Coppola A, Andria G, Cerbone AM, Madonna P, Tufano A, Falco A, Marchesani P, Ciabattoni G, Patrono C. Oxidative stress and platelet activation in homozygous homocystinuria. Circulation 2001; 104: 1124-8.
    CrossrefPubMedGoogle Scholar